TODAY'S HEADLINES

Are PCSK9 inhibitors too pricey?

PCSK9 inhibitors such as alirocumab (Praluent) and evolocumab (Repatha) are priced too high to benefit the US healthcare system, according to a new study. Read more

New drug approved for chemotherapy nausea

FDA recently approved granisetron (Sustol) extended-release injection to prevent nausea and vomiting associated with repeat courses of chemotherapy. Read more

CONTINUING PHARMACY EDUCATION

Interventions to improve quality of life for patients with psoriasis and psoriatic arthritis

This month's CE activity, "Interventions to improve quality of life for patients with psoriasis and psoriatic arthritis," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians about pharmacist intervention in improving the quality of life for patients with psoriasis and psoriatic arthritis.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

PBM giants pare down drug expenses

Express Scripts and CVS Health recently announced they are cutting out certain blockbuster drugs from their 2017 formularies.  Which drugs are impacted

August 24, 2016

Related Articles

Move over Sovaldi: Could PCSK9 inhibitors be a bigger cost challenge?

First chemotherapy antidote available soon